Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site

Abstract

TP53 is the most frequently mutated gene in cancer, yet these mutations remain therapeutically non-actionable. Major challenges in drugging p53 mutations include heterogeneous mechanisms of inactivation and the absence of broadly applicable allosteric sites. Here we report the identification of small molecules, including arsenic trioxide (ATO), an established agent in treating acute promyelocytic leukemia, as cysteine-reactive compounds that rescue structural p53 mutations. Crystal structures of arsenic-bound p53 mutants reveal a cryptic allosteric site involving three arsenic-coordinating cysteines within the DNA-binding domain, distal to the zinc-binding site. Arsenic binding stabilizes the DNA-binding loop-sheet-helix motif alongside the overall β-sandwich fold, endowing p53 mutants with thermostability and transcriptional activity. In cellular and mouse xenograft models, ATO reactivates mutant p53 for tumor suppression. Investigation of the 25 most frequent p53 mutations informs patient stratification for clinical exploration. Our results provide a mechanistic basis for repurposing ATO to target p53 mutations for widely applicable yet personalized cancer therapies.

Keywords: arsenic trioxide; crystal structure; drug discovery; p53; patient stratification; precision medicine; tumor suppression.

Conflict of interest statement

Declaration of Interests M.L., J.-L.W., and H.-X.S. are co-authors of the pending patents “PANDA as a novel therapeutic” (PCT/CN2018/085190) and “mp53 rescue compounds and methods of treating a p53 disorder” (PCT/CN2019/070117). The authors declare no other competing interests.

Copyright © 2020 Elsevier Inc. All rights reserved.